Metagenomi Therapeutics, Inc Financials
This page shows Metagenomi Therapeutics, Inc (MGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Metagenomi Therapeutics, Inc has an operating margin of -170.0%, meaning the company retains $-170 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -175.4% the prior year.
Metagenomi Therapeutics, Inc's revenue surged 16.8% year-over-year to $52.3M, reflecting rapid business expansion. This strong growth earns a score of 77/100.
Metagenomi Therapeutics, Inc carries a low D/E ratio of 0.38, meaning only $0.38 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.91, Metagenomi Therapeutics, Inc holds $6.91 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Metagenomi Therapeutics, Inc generated -$109.1M in operating cash flow, capex of $3.1M consumed most of it, leaving -$112.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Metagenomi Therapeutics, Inc passes 2 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Metagenomi Therapeutics, Inc generates $1.40 in operating cash flow (-$109.1M OCF vs -$78.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Metagenomi Therapeutics, Inc generated $52.3M in revenue in fiscal year 2024. This represents an increase of 16.8% from the prior year.
Metagenomi Therapeutics, Inc's EBITDA was -$83.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.4% from the prior year.
Metagenomi Therapeutics, Inc generated -$112.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 10.8% from the prior year.
Metagenomi Therapeutics, Inc reported -$78.1M in net income in fiscal year 2024. This represents a decrease of 14.4% from the prior year.
Metagenomi Therapeutics, Inc earned $-2.36 per diluted share (EPS) in fiscal year 2024. This represents an increase of 88.2% from the prior year.
Metagenomi Therapeutics, Inc held $27.4M in cash against $0 in long-term debt as of fiscal year 2024.
Metagenomi Therapeutics, Inc had 37M shares outstanding in fiscal year 2024. This represents an increase of 999.1% from the prior year.
Metagenomi Therapeutics, Inc's operating margin was -170.0% in fiscal year 2024, reflecting core business profitability. This is up 5.4 percentage points from the prior year.
Metagenomi Therapeutics, Inc's net profit margin was -149.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 3.2 percentage points from the prior year.
Metagenomi Therapeutics, Inc invested $109.2M in research and development in fiscal year 2024. This represents an increase of 15.7% from the prior year.
Metagenomi Therapeutics, Inc invested $3.1M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 68.3% from the prior year.
MGX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.7M+1.7% | $8.5M+106.3% | $4.1M-57.1% | $9.6M-51.9% | $20.0M+79.3% | $11.2M-10.0% | $12.4M+0.3% | $12.4M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $25.3M+12.3% | $22.5M-10.5% | $25.1M+8.5% | $23.2M-18.2% | $28.3M-9.9% | $31.4M+27.0% | $24.8M-7.8% | $26.8M |
| SG&A Expenses | $6.2M-11.1% | $7.0M+2.8% | $6.8M-3.8% | $7.1M-17.3% | $8.6M-2.3% | $8.8M+11.6% | $7.8M-1.0% | $7.9M |
| Operating Income | -$22.8M-8.8% | -$21.0M+24.6% | -$27.8M-34.9% | -$20.6M-22.3% | -$16.9M+41.9% | -$29.0M-43.8% | -$20.2M+9.8% | -$22.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$234K-631.8% | $44K-55.1% | $98K+108.1% | -$1.2M+45.1% | -$2.2M | $0-100.0% | $7.1M+490.4% | $1.2M |
| Net Income | -$20.4M-2.4% | -$19.9M+20.5% | -$25.0M-7.0% | -$23.4M-117.9% | -$10.7M+57.3% | -$25.1M-30.3% | -$19.3M+2.7% | -$19.8M |
| EPS (Diluted) | $-0.55-1.9% | $-0.54+20.6% | $-0.68-83.8% | $-0.37-27.6% | $-0.29+75.6% | $-1.19 | $-5.67+2.6% | $-5.82 |
MGX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $247.9M-8.9% | $272.3M-8.6% | $297.9M-8.2% | $324.6M-15.9% | $385.9M-7.1% | $415.4M+13.9% | $364.8M | N/A |
| Current Assets | $189.8M-10.3% | $211.7M-9.2% | $233.2M-9.6% | $258.0M-16.1% | $307.6M-8.4% | $335.6M+20.6% | $278.3M | N/A |
| Cash & Equivalents | $32.8M+22.1% | $26.9M-8.0% | $29.2M+6.6% | $27.4M-55.2% | $61.2M-40.3% | $102.6M-27.1% | $140.6M+38.0% | $101.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | $900K0.0% | $900K-18.2% | $1.1M | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $69.5M-9.1% | $76.5M-10.3% | $85.2M-5.1% | $89.7M-23.0% | $116.5M-16.7% | $139.8M-72.1% | $500.4M | N/A |
| Current Liabilities | $29.6M-11.1% | $33.3M-16.6% | $39.9M+6.9% | $37.3M-29.4% | $52.8M-25.3% | $70.7M+2.7% | $68.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $178.4M-8.9% | $195.8M-7.9% | $212.7M-9.5% | $234.9M-12.8% | $269.4M-2.3% | $275.6M+303.3% | -$135.6M-113816.0% | -$119K |
| Retained Earnings | -$288.3M-7.6% | -$267.9M-8.0% | -$248.0M-11.2% | -$223.0M-23.3% | -$180.8M-6.3% | -$170.1M-17.4% | -$144.9M | N/A |
MGX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.3M0.0% | -$21.3M+7.0% | -$22.8M+13.1% | -$26.3M+0.1% | -$26.3M+11.9% | -$29.9M-45.0% | -$20.6M+13.2% | -$23.7M |
| Capital Expenditures | $74K-41.7% | $127K-55.9% | $288K-13.8% | $334K-49.8% | $665K-27.3% | $915K-47.3% | $1.7M-23.1% | $2.3M |
| Free Cash Flow | -$21.3M+0.2% | -$21.4M+7.6% | -$23.1M+13.1% | -$26.6M+1.3% | -$27.0M+12.3% | -$30.8M-37.8% | -$22.3M+14.1% | -$26.0M |
| Investing Cash Flow | $27.4M+43.5% | $19.1M-22.9% | $24.7M-13.4% | $28.5M+319.0% | -$13.0M+86.2% | -$94.7M-256.2% | $60.6M-20.1% | $75.9M |
| Financing Cash Flow | -$187K-12.7% | -$166K-115.6% | -$77K | $0+100.0% | -$2.0M-102.3% | $86.5M+6587.0% | -$1.3M+30.2% | -$1.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MGX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -263.8%-17.2pp | -246.5%+427.6pp | -674.1%-459.6pp | -214.5%-130.2pp | -84.3%+175.9pp | -260.2%-97.3pp | -162.9%+18.3pp | -181.2% |
| Net Margin | -235.5%-1.7pp | -233.8%+372.9pp | -606.7%-363.3pp | -243.4%-189.7pp | -53.7%+171.7pp | -225.4%-69.8pp | -155.6%+4.7pp | -160.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.2%-0.9pp | -7.3%+1.1pp | -8.4%-1.2pp | -7.2%-4.4pp | -2.8%+3.3pp | -6.0%-0.8pp | -5.3% | N/A |
| Current Ratio | 6.42+0.1 | 6.36+0.5 | 5.85-1.1 | 6.91+1.1 | 5.82+1.1 | 4.75+0.7 | 4.04 | N/A |
| Debt-to-Equity | 0.390.0 | 0.39-0.0 | 0.40+0.0 | 0.38-0.1 | 0.43-0.1 | 0.51+4.2 | -3.69 | N/A |
| FCF Margin | -246.3%+4.8pp | -251.1%+309.3pp | -560.5%-283.7pp | -276.8%-142.0pp | -134.8%+140.9pp | -275.7%-95.6pp | -180.1%+30.1pp | -210.2% |
Similar Companies
Frequently Asked Questions
What is Metagenomi Therapeutics, Inc's annual revenue?
Metagenomi Therapeutics, Inc (MGX) reported $52.3M in total revenue for fiscal year 2024. This represents a 16.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Metagenomi Therapeutics, Inc's revenue growing?
Metagenomi Therapeutics, Inc (MGX) revenue grew by 16.8% year-over-year, from $44.8M to $52.3M in fiscal year 2024.
Is Metagenomi Therapeutics, Inc profitable?
No, Metagenomi Therapeutics, Inc (MGX) reported a net income of -$78.1M in fiscal year 2024, with a net profit margin of -149.3%.
What is Metagenomi Therapeutics, Inc's earnings per share (EPS)?
Metagenomi Therapeutics, Inc (MGX) reported diluted earnings per share of $-2.36 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Metagenomi Therapeutics, Inc's EBITDA?
Metagenomi Therapeutics, Inc (MGX) had EBITDA of -$83.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Metagenomi Therapeutics, Inc's operating margin?
Metagenomi Therapeutics, Inc (MGX) had an operating margin of -170.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Metagenomi Therapeutics, Inc's net profit margin?
Metagenomi Therapeutics, Inc (MGX) had a net profit margin of -149.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Metagenomi Therapeutics, Inc's free cash flow?
Metagenomi Therapeutics, Inc (MGX) generated -$112.2M in free cash flow during fiscal year 2024. This represents a -10.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Metagenomi Therapeutics, Inc's operating cash flow?
Metagenomi Therapeutics, Inc (MGX) generated -$109.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Metagenomi Therapeutics, Inc's total assets?
Metagenomi Therapeutics, Inc (MGX) had $324.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Metagenomi Therapeutics, Inc's capital expenditures?
Metagenomi Therapeutics, Inc (MGX) invested $3.1M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Metagenomi Therapeutics, Inc spend on research and development?
Metagenomi Therapeutics, Inc (MGX) invested $109.2M in research and development during fiscal year 2024.
How many shares does Metagenomi Therapeutics, Inc have outstanding?
Metagenomi Therapeutics, Inc (MGX) had 37M shares outstanding as of fiscal year 2024.
What is Metagenomi Therapeutics, Inc's current ratio?
Metagenomi Therapeutics, Inc (MGX) had a current ratio of 6.91 as of fiscal year 2024, which is generally considered healthy.
What is Metagenomi Therapeutics, Inc's debt-to-equity ratio?
Metagenomi Therapeutics, Inc (MGX) had a debt-to-equity ratio of 0.38 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Metagenomi Therapeutics, Inc's return on assets (ROA)?
Metagenomi Therapeutics, Inc (MGX) had a return on assets of -24.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Metagenomi Therapeutics, Inc's cash runway?
Based on fiscal year 2024 data, Metagenomi Therapeutics, Inc (MGX) had $27.4M in cash against an annual operating cash burn of $109.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Metagenomi Therapeutics, Inc's Piotroski F-Score?
Metagenomi Therapeutics, Inc (MGX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Metagenomi Therapeutics, Inc's earnings high quality?
Metagenomi Therapeutics, Inc (MGX) has an earnings quality ratio of 1.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Metagenomi Therapeutics, Inc?
Metagenomi Therapeutics, Inc (MGX) scores 55 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.